1. Home >
  2. M&A >
  3. Venture >
  4. United Kingdom >
  5. Calculus Capital Invests In eConsult

Investment Summary

Calculus Capital Invests In eConsult

On February 4, 2021, private equity firm Calculus Capital invested in internet software and services company eConsult

Investment Highlights
  • This is Calculus Capital’s 6th transaction in the Internet Software and Services sector.
  • This is Calculus Capital’s 35th transaction in the United Kingdom.

Investment Summary
Date 2021-02-04
Target eConsult
Sector Internet Software and Services
Investor(s) Calculus Capital
Deal Type Venture

Target

eConsult

London, United Kingdom
eConsult is a provider of digital gateway for clinicians to efficiently records patient details, case history, symptoms, and provides them to the GP in a concise format where they are processed in 2-3 minutes. eConsult Health is based in London, United Kingdom.

Search 215,130 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Calculus Capital

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1999
Size Small
Type Sector Agnostic
DESCRIPTION

Calculus Capital is a UK-based investment group focused on fast-growth companies. Calculus Capital is sector agnostic and looks to commit £2 to £5 million per investment. Calculus Capital is based in London.

DEAL STATS #
Overall 36 of 47
Sector: Internet Software and Services M&A 6 of 7
Type: Venture M&A Deals 7 of 8
Country: United Kingdom M&A 35 of 45
Year: 2021 M&A 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-29 Chop’d

London, United Kingdom

Chop’d is a operater of salad bar restaurant chains with 14+ sites. Chop’d was founded in 2002 and is based in London, United Kingdom.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-19 Axol

Easter Bush, United Kingdom

Axol is a biotechnology company specialising in human induced pluripotent stem cell (iPSC) technology. It develops and supplies iPSC lines and functional cell models, offering custom reprogramming, gene editing, and differentiation services to accelerate drug discovery and disease modelling across neuroscience, cardiovascular, ophthalmology, and dermatology. Axol was founded in 2013 and is based in Easter Bush, United Kingdom.

Buy -
Mergr

Solution for

Product

Company

Legal